Compare Grab Holdings Ltd. (GRAB) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Grab Holdings Ltd. vs State Street SPDR S&P Biotech ETF — how do they compare? Grab Holdings Ltd. trades at $3.21 (market cap $12.72B), while State Street SPDR S&P Biotech ETF trades at $153.61 (market cap $10.11B). The key difference: Grab Holdings Ltd. is the larger of the two by market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Grab Holdings Ltd. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Grab Holdings Ltd. for 94 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| GRAB | XBI | |
|---|---|---|
Market Cap | $12.72B | $10.11B |
Volume | 65,352,859 | 12,903,266 |
Sector | Technology | Broad Market / Factor |
52-Week High | $6.17 | $169.55 |
52-Week Low | $2.80 | $104.99 |
Typical Hold Time | 94 Days | 37 Days |
Enterprise Value | $8.46B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GRAB trades at $3.08, up 0.33% with bearish technical signals but strong fundamentals. The company achieved profitability in 2025 with $268M net income and has beaten earnings estimates for three consecutive quarters. Recent developments include a $1.49B acquisition of Atome Financial and $30M in insider buying by the CEO, signaling confidence in growth prospects despite recent stock pressure.
GRAB presents a compelling turnaround story with accelerating revenue growth and margin expansion. The risk-reward appears favorable given the 92% analyst buy rating, though investors should monitor integration risks from the Atome acquisition and competitive pressures in Southeast Asian markets that could impact future profitability.
XBI trades at $153.34, up 2.07% today, but faces bearish technical signals with 17 sell indicators versus 4 buys. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Current price sits near resistance at $154, with support at $147.
Biotech sector optimism is growing with cancer vaccine breakthroughs and improved capital access, though XBI's 0.35% expense ratio is higher than broader healthcare ETFs. Key risks include sector volatility and regulatory uncertainty, while analyst consensus remains neutral with 100% hold rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Grab Holdings Ltd.
Grab Holdings Limited operates as a holding company. The Company, through its subsidiaries, develops delivery management, mobility, financial services, and enterprise software solutions. Grab Holdings serves customers worldwide.
Read more on GRAB →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
